Preservation of pancreatic islet grafts in the extrahepatic space
US-2026076999-A1 · Mar 19, 2026 · US
Markers of definitive endoderm
US9605243B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9605243-B2 |
| Application number | US-201314066441-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 29, 2013 |
| Priority date | Dec 23, 2003 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. An in vitro method of producing cells which express thyroid transcription factor 1 (TITF1) from mammalian definitive endoderm cells comprising the steps of: (i) culturing mammalian definitive endoderm cells with an effective amount of Wnt3a for at least 7 days, (ii) enriching for cells which express TITF1. 2. The in vitro method of claim 1 , wherein step (i) further comprises providing less than 2% serum to the definitive endoderm cells.
Assignees
Inventors
Classifications
- C12N5/0617Primary
Thyroid and parathyroid glands · CPC title
- A61K35/407Primary
Liver; Hepatocytes · CPC title
Activin; Inhibin; Mullerian inhibiting substance · CPC title
- C12N5/0603Primary
Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies · CPC title
Stomach; Intestine; Goblet cells; Oral mucosa; Saliva · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9605243B2 cover?
- Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.
- Who is the assignee on this patent?
- Viacyte Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0617. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).